Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study

Abstract We investigated the incidence of cardiotoxicity, its risk factors, and the clinical course of cardiac function in patients with malignant lymphoma (ML) who received a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Among all ML patients who received a CHOP regim...

Full description

Bibliographic Details
Main Authors: Takafumi Nakayama, Yoshiko Oshima, Shigeru Kusumoto, Junki Yamamoto, Satoshi Osaga, Haruna Fujinami, Takaki Kikuchi, Tomotaka Suzuki, Haruhito Totani, Shiori Kinoshita, Tomoko Narita, Asahi Ito, Masaki Ri, Hirokazu Komatsu, Kazuaki Wakami, Toshihiko Goto, Tomonori Sugiura, Yoshihiro Seo, Nobuyuki Ohte, Shinsuke Iida
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:eJHaem
Subjects:
anthracycline‐induced cardiotoxicity
CHOP regimen
malignant lymphoma
re‐cardiotoxicity
recovery from cardiotoxicity
Online Access:https://doi.org/10.1002/jha2.110

Internet

https://doi.org/10.1002/jha2.110

Similar Items